Harry A. Peters - Concepedia

Concepedia

Author

Harry A. Peters

Rotterdam University of Applied Sciences

Also Known As

H A Peters, H PETERS, H Peters, H. A. Peters, H. Peters, H.A Peters, H.A. Peters, Harry A Peters, Harry A. Peters, Harry Peters

44

Publications

2.7K

Citations

22

H-Index

29

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus University Rotterdam Erasmus MC Radboud University Nijmegen

HA

About

Harry A. Peters is an author at Rotterdam University of Applied Sciences specializing in medicine, cancer research, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.5K
2	Cell Biology	3	3	655
3	Immunology	3	3	834
4	Biochemistry	1	1	25
5	Endocrinology	1	1	117

Harry A. Peters

×

22

Publications

2.7K

Citations

21

H-Index

	Year	Citations
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. John A. Foekens, Harry A. Peters, Maxime P. Look, PubMed Tumor BiologyBreast OncologyOncologyPlasminogen ActivationBreast Cancer Patients	2000	429
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. John A. Foekens, Harry A. Peters, Nicolaï Grebenchtchikov, PubMed Breast OncologyImmunologyPathologyTumor BiologyAdvanced Breast Cancer	2001	300
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. John A. Foekens, Manfred Schmitt, W L van Putten, PubMed UrologyBreast OncologyEndocrine-related CancerMedicinePrognostic Value	1992	231
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. John A. Foekens, Manfred Schmitt, W L van Putten, Journal of Clinical Oncology	1994	225
The MTT Tetrazolium Salt Assay Scrutinized: How to Use this Assay Reliably to Measure Metabolie Activity of Cell Cultures in vitro for the Assessment of Growth Characteristics, IC<sub>50</sub>-Values and Cell Survival Anieta M. Sieuwerts, Jan G.M. Klijn, Harry A. Peters, Clinical Chemistry and Laboratory Medicine (CCLM)	1995	200
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. J Grøndahl-Hansen, Harry A. Peters, W L van Putten, PubMed Type 1Urokinase Plasminogen ActivatorUrologyOncologyEndocrine-related Cancer	1995	174
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer John A. Foekens, Maxime P. Look, Harry A. Peters, JNCI Journal of the National Cancer Institute	1995	157
Prognostic significance of cathepsins B and L in primary human breast cancer. John A. Foekens, Janko Kos, Harry A. Peters, Journal of Clinical Oncology	1998	147
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer Anne‐Sofie Schrohl, Mads Holten-Andersen, Harry A. Peters, Clinical Cancer Research	2004	123
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. John A. Foekens, Henk Portengen, W L van Putten, PubMed Breast OncologyGynecologyMammary Gland DevelopmentTumor BiologyDcc Assays	1989	117

Page 1